Skip to Content
Merck
All Photos(1)

Documents

05-765

Sigma-Aldrich

Anti-MLL/HRX Antibody, CT., clone 9-12

clone 9-12, Upstate®, from mouse

Synonym(s):

Histone-lysine N-methyltransferase 2A, Lysine N-methyltransferase 2A, ALL-1, CXXC-type zinc finger protein 7, Myeloid/lymphoid or mixed-lineage leukemia, Myeloid/lymphoid or mixed-lineage leukemia protein 1, Trithorax-like protein, Zinc finger protein HR

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

9-12, monoclonal

species reactivity

mouse, human

manufacturer/tradename

Upstate®

technique(s)

ChIP: suitable
immunofluorescence: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... KMT2A(4297)

General description

The acute lymphoblastic leukaemia (ALL)-1 (also known as MLL, HRX, HTRX, and TRX1) gene on human chromosome 11q23 is the site of many locally clustered chromosomal alterations associated with several types of acute leukaemias, including deletions, partial duplications and translocations. Structurally variant proteins derived from the altered gene presumably cause the malignant transformation of early haemopoietic progenitor cells.

Specificity

This monoclonal antibody targets the C-terminal proteolytic fragment of MLL (C180; MLLC). A reduced target band detection by this antibody was seen lysate from G411NS human glioblastoma neural stem cells transfected with MLL shRNA (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Immunogen

Epitope: MLL C-terminal fragment
MBP-tagged recombinant human mixed lineage leukemia (MLL) protein C-terminal fragment (a.a. 3084-3959).

Application

Anti-MLL/HRX, C-term., clone 9-12 is a high quality mouse monoclonal antibody that has been validated and published for use in Chromatin Immunoprecipitation (ChIP), Immunofluorescence, Immunoprecipitation, and Western Blotting applications.
Immnuofluorescence Analysis: A representative lot detected MLL expression in SOX2+ cells in paraffin-embedded high-grade human gliomas sections (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the Hoxa10 and Meis promoters in mouse MLL-AF10 leukemia cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected an enhanced MLL occupancy at the Ink4a locus of 8-month-old than 2-month-old bEzTG mouse islets. The same age-dependent Ink4a locus enrichment was observed with H3K4me3, while the opposite trend was seen with Ezh and H3K27me3 enrichment at the same locus (Zhou, J.X., et al. (2013). J. Clin. Invest. 123(11):4849-4858).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the HOXA10 promoter region in G179NS and G411NS human glioblastoma neural stem cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the DNA replication origin (RD) as well as at both exon 1b and p16INK4a/p19ARF shared exon 2 in mouse embryonic fibroblast (MEF). An increased MLL enrichment at these sites was observed in senescent and Polycomb mutant MEFs (Agherbi, H., et al. (2009). PLoS One. 4(5):e5622).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the Hoxa9 AB region using mouse embryonic fibroblast (MEF) chromatin preparation (Erfurth, F.E., et al. (2008). Proc. Natl. Acad. Sci. U.S.A. 105(21):7517-7522).

Immnuoprecipitation Analysis: A representative lot co-immunoprecipitated JmjD3 and RbBP5, but not Dnmt3a, with MLL from Min6 mouse insulinoma cell extract (Zhou, J.X., et al. (2013). J. Clin. Invest. 123(11):4849-4858).

Western Blotting Analysis: A representative lot detected higher MLL level in cultured glioblastoma neural stem (GNS) cells than neural stem (NS) cells, as well as MLL enrichment in the CD15+ fraction of freshly resected Glioblastoma (GBM) cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Western Blotting Analysis: A representative lot detected SET domain-containing C-terminal fragment of the MLL complex enzymatic subunit MLL (C180; MLLC) in anti-FLAG immunoprecipitate from HeLaS cells stably expressing FLAG-tagged hDPY-30 (Cho, Y.W., et al. (2007). J. Biol. Chem. 282(28):20395-20406).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Histones

Quality

Evaluated by Western Blotting in K562 nuclear extract.
Western Blotting Analysis: 0.1-1 µg/mL of this antibody detected MLL C-terminal fragment (C180; MLLC) in K562 nuclear extract.

Target description

~180 kDa observed. 134.4 kDa (a.a. 2719-3969; human MLL cleavage product C180) and 431.8/427.7/432.1 kDa (human full-length MLL isoform 1/2 (14P-18B)/3) calculated.

Physical form

Format: Purified
Protein G purified.
Purified mouse IgG1 in 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide before the addition of glycerol to 30%. Liquid at -20ºC

Storage and Stability

Store for 2 years at -20ºC from date of shipment. For maximum recovery of product, centrifuge the vial prior to removing the cap.

Analysis Note

Control
K562 nuclear extract

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression.
Erfurth, FE; Popovic, R; Grembecka, J; Cierpicki, T; Theisler, C; Xia, ZB; Stuart et al.
Proceedings of the National Academy of Sciences of the USA null
Laurie K Svoboda et al.
Oncotarget, 8(1), 458-471 (2016-11-27)
Developmental transcription programs are epigenetically regulated by the competing actions of polycomb and trithorax (TrxG) protein complexes, which repress and activate genes, respectively. Ewing sarcoma is a developmental tumor that is associated with widespread de-regulation of developmental transcription programs, including
Zhang Feng et al.
Frontiers in neuroanatomy, 14, 36-36 (2020-08-15)
Neuron apoptosis in ischemic penumbra was proved to be involved in ischemic stroke (IS) development and contributed to the poor prognosis of IS. Recent studies showed that aberrant trimethylation of histone H3 lysine 4 (H3K4me3) level was associated with cell
Tiziana Fioretti et al.
Cell biochemistry and function, 40(7), 706-717 (2022-08-19)
The chromosomal translocation t(4;11)(q21;q23), a hallmark of an aggressive form of acute lymphoblastic leukemia (ALL), encodes mixed-lineage leukemia (MLL)-AF4 oncogenic chimera that triggers aberrant transcription of genes involved in lymphocyte differentiation, including HOXA9 and MEIS1. The scaffold protein 14-3-3θ, which
Hsu-Ping Kuo et al.
Cancer cell, 24(4), 423-437 (2013-09-24)
MLL fusion proteins in leukemia induce aberrant transcriptional elongation and associated chromatin perturbations; however, the upstream signaling pathways and activators that recruit or retain MLL oncoproteins at initiated promoters are unknown. Through functional and comparative genomic studies, we identified an

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service